Clarification from the UK Kidney Association on kidney patients who're eligible for the third COVID-19 vaccination has been issued.
The JCVI advises that a third dose should be offered to people over 12 who were severely immunosuppressed at the time of their first or second dose, including those with leukaemia, advanced HIV and organ transplant recipients.
We provide some quick facts here on COVID-19 for people with autosomal dominant polycystic kidney disease (ADPKD). The situation keeps changing and rules can differ by area.
Healx, the AI-powered, patient-inspired technology company accelerating the discovery and development of rare disease treatments at scale, today announced that it would be collaborating with the PKD Charity to identify and progress novel treatments for Autosomal Dominant Polycystic Kidney Disease (ADPKD) and Autosomal Recessive Polycystic Kidney Disease (ARPKD).
We’re delighted to announce a major award from the National Institute for Health Research (NIHR) - the nation's largest funder of health and care research - to study pain in Autosomal Dominant Polycystic Kidney Disease (ADPKD).
The PKD Charity has awarded £10,000 to Newcastle University to analyse the cilia in kidney cells from ADPKD patients.
We have succeeded in securing funding from the National Lottery Community Fund for our PKD Positive Peers Programme - a 5-year programme of vital support activities to help patients and families to deal with the traumatic and often devastating effects of polycystic kidney disease (PKD).
The Bill is expected to become law in Spring 2020. From then, all adults over 18 in England will be considered as a possible organ donor when they die, unless they choose to opt out or are excluded. This is commonly referred to as an ‘opt out’ system.